APG Asset Management US Inc. Invests $346,000 in Hologic, Inc. (NASDAQ:HOLX)

APG Asset Management US Inc. purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,800 shares of the medical equipment provider's stock, valued at approximately $346,000.

A number of other institutional investors also recently bought and sold shares of the business. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter worth $26,000. Groupama Asset Managment grew its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

HOLX stock traded down $0.95 during midday trading on Tuesday, reaching $57.89. The stock had a trading volume of 682,678 shares, compared to its average volume of 1,916,586. Hologic, Inc. has a 52-week low of $56.27 and a 52-week high of $84.67. The company has a market cap of $12.99 billion, a price-to-earnings ratio of 18.26, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. The company's fifty day simple moving average is $62.19 and its 200 day simple moving average is $71.34. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of analyst reports. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Royal Bank of Canada decreased their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research note on Thursday, February 6th. Stephens restated an "overweight" rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley decreased their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.